Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| GRAL | Grail | $50.21 | -$51.32 | -50.55% | 15.5M | $2.0B | $20.44$118.84 |
| WSHP | WeShop | $22.53 | -$18.47 | -45.05% | 166.3K | $528M | $20.02$250.00 |
| AIDX | 20/20 Biolabs | $14.78 | -$9.07 | -38.04% | 27.7K | $73M | $13.00$50.00 |
| CCOI | Cogent Communications | $18.60 | -$7.71 | -29.30% | 361.1K | $913M | $15.96$80.45 |
| FROG | JFrog | $38.01 | -$12.29 | -24.43% | 623.4K | $4.5B | $27.00$70.43 |
| RIME | Algorhythm Holdings, Inc. | $2.11 | -$0.53 | -20.08% | 6.7M | $5.7M | $0.73$4.58 |
| OKTG | Themes ETF Trust - Leverage Shares 2x Long Okta Daily ETF | $10.71 | -$2.48 | -18.83% | 3.6K | - | $10.70$19.10 |
| NBIL | GraniteShares ETF Trust - GraniteShares 2x Long Nbis Daily ETF | $10.70 | -$2.34 | -17.95% | 3.3M | - | $6.37$38.58 |
| NBIG | Themes ETF Trust - Leverage Shares 2x Long Nbis Daily ETF | $7.59 | -$1.65 | -17.86% | 959.9K | - | $4.51$19.45 |
| ANPA | Rich Sparkle | $9.32 | -$1.87 | -16.71% | 3M | $117M | $2.80$180.64 |
| CC | Chemours | $17.01 | -$3.41 | -16.68% | 463.7K | $2.6B | $9.13$21.85 |
| CRWG | Themes ETF Trust - Leverage Shares 2x Long Crwv Daily ETF | $3.62 | -$0.72 | -16.59% | 29.5M | - | $2.42$19.63 |
| CLRO | ClearOne | $5.26 | -$1.04 | -16.44% | 20.7K | $12M | $3.83$15.42 |
| NETG | Themes ETF Trust - Leverage Shares 2x Long Net Daily ETF | $9.44 | -$1.84 | -16.30% | 57.6K | - | $8.00$15.11 |
| MTUS | Metallus | $17.58 | -$3.35 | -16.01% | 60.1K | $732M | $10.78$21.73 |
| EDHL | Everbright Digital | $2.84 | -$0.54 | -15.98% | 1.9M | - | $2.22$110.08 |
| CRWL | GraniteShares ETF Trust - GraniteShares 2x Long Crwd Daily ETF | $19.86 | -$3.72 | -15.78% | 528.8K | - | $15.77$46.34 |
| OBAI | Tg-17 | $2.10 | -$0.38 | -15.32% | 1.8M | $22M | $2.03$38.50 |
| BAIG | Themes ETF Trust - Leverage Shares 2x Long Bbai Daily ETF | $3.84 | -$0.69 | -15.23% | 397.1K | - | $3.72$36.03 |
| IREG | Themes ETF Trust - Leverage Shares 2x Long Iren Daily ETF | $14.77 | -$2.64 | -15.17% | 89.1K | - | $12.86$41.60 |
| RKLX | Tidal Trust II - Defiance Daily Target 2x Long Rklb ETF | $35.25 | -$6.26 | -15.08% | 2.3M | - | $3.32$78.00 |
| ARDX | Ardelyx | $5.73 | -$1.01 | -14.98% | 14M | $1.4B | $3.21$8.40 |
| HRMY | Harmony Biosciences | $29.27 | -$5.12 | -14.89% | 551.3K | $1.7B | $25.52$40.87 |
Related Articles
Featured Article
How Harmony Biosciences Can Prove Its Skeptics Wrong
Dan Caplinger|Jan 28, 2026
The biotech company is looking for multiple successes in the coming years.

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
Dan Caplinger|Jan 27, 2026
Some investors haven't gotten answers to their questions about the biotech stock's past and future.

I Was Shocked to Find This Value-Priced Biotech Growth Stock
Dan Caplinger|Jan 26, 2026
But deciding if it's a good buy takes a little more looking.

Here's Why Grail Soared, Again, in November
Lee Samaha|Dec 2, 2025
A combination of operational improvements and developments at its key rival bolstered the stock recently.

Here's Why Grail Stock Exploded Higher by 55% in October
Lee Samaha|Nov 6, 2025
The company demonstrated tangible progress on its path to profitability.

Grail Stock Is Up 80% Over the Past Month. Here's Why.
Matthew Benjamin|Oct 23, 2025
This cancer detection test maker just got some great news.

This Cancer Detection Pioneer Is Worth a Look
Matthew Benjamin|Sep 26, 2025
Multicancer detection tests are closing in on FDA approval and potentially major sales.

This Industrial Stock Looks Dirt Cheap. Is It a Buy?
Tyler Crowe|Dec 2, 2022
There is a lot to like about The Chemours Company, but there is one issue that should give investors pause.

2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
Cory Renauer|Nov 20, 2022
Recent analyst upgrades suggest these stocks can triple your money or better.

Investors Are Paying Attention to This Pharma That Is Gaining Speed
Jeffrey Little|Jul 8, 2022
Can turning one product into a portfolio of products result in revenue magic?
